Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
Phone:+1 866 267 4479
Request a Proposal
Phone:400 881 0237
Phone:01 208 94 060
Phone:+44 203 564 4649
With the complexity of oncology clinical trials, how can you succeed – or fail – faster?
Translational research helps you understand a compound’s biology, critical for developing targeted therapies. Quintiles’ Translational R&D Center for Excellence provides scientific insight into targets, molecular signaling and clinical outcomes.
Molecule to Medicine: The Biomarker Frontier
Quintiles can help you map stakeholder requirements and integrate these into the development process from the very beginning, incorporating critical endpoints to drive more efficient clinical trials.
Achieving Real Results in Oncology
Quintiles brings together experienced oncology teams and integrated global trial operations to help our customers achieve real results in oncology clinical development.
CardioCheck: A Biomarker Assay Program
Prospective identification and potential amelioration of cardiotoxicity is a critical component of contemporary drug development.
Read white paper
The Power of Integration in Oncology
Quintiles is partnering early with oncology drug developers, providing integrated services spanning Phase 1 through commercialization to help them achieve real results in their oncology programs. By combining scientific and therapeutic expertise with operational insights, we can gather evidence needed to support clinical utility, help gain regulatory approval, and accelerate market adoption. As a testament to our commitment, we helped develop or commercialize the world’s top 45 best-selling oncology drugs of 2012.